Walgreens has announced a partnership with Prothena to speed up identification and enrolment of patients for the latter’s Phase l ASCENT-2 multiple ascending dose trial of PRX012 to treat Alzheimer’s disease.
Under the tie-up, Walgreens will use its presence across the US, portfolio of healthcare firms and compliance framework to match patients for the trial.
Walgreens’ pharmacy teams currently operate in around 9,000 locations and have the capability to help patients meet their specific requirements and remove barriers to care.
The firm will use its pharmacy and patient-authorised clinical information to recognise and engage with possibly eligible patients and their caregivers at various places, including pharmacy, home or digitally, to inform them about the ASCENT-2 trial.
Interested patients or their caregivers will then be called upon to undergo a pre-screen to decide on their eligibility to join one of Prothena’s clinical trial sites.
These endeavours are in line with the Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act that aims to accelerate the participation of underrepresented populations in Alzheimer’s and dementia trials.
ASCENT-2 will examine the safety and tolerability of PRX012, a potential anti-amyloid beta antibody that is currently being developed for Alzheimer’s treatment.
Topline data from the ongoing ASCENT-2 single ascending dose (SAD) and multiple ascending dose (MAD) trials are anticipated to be released by the end of this year.
Walgreens chief clinical trials officer Ramita Tandon said: “Through Walgreens trusted community pharmacy presence and daily interactions with millions of patients across America, we believe we can have a meaningful impact in helping Prothena with their clinical trial recruitment efforts.
“Our aim is to help build a more representative patient population for Alzheimer’s research, particularly among underserved and diverse communities, to create a better understanding of this disease.”
In June last year, Walgreens introduced its clinical trial business to reshape the patient experience and boost access and retention in drug development research led by sponsors.